SCHEMBL22235293

SCHEMBL22235293

CN1CCC(C(=O)CCl)CC1=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.42
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC3 O15379 1/20 0.36
P2RX7 Q99572 1/20 0.35
ALDH1A1 P00352 2/20 0.34
POLB P06746 2/20 0.33
HSD17B10 Q99714 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
BRD2 P25440 1/20 0.32
OPRL1 P41146 1/20 0.32
HTR5A P47898 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KDM4E B2RXH2 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16887543 0.84 BRD4 (0.43) BRD4HDAC1HDAC2HDAC3P2RX7
SCHEMBL22234986 0.81 BRD4 (0.44) BRD4HDAC1HDAC2HDAC3P2RX7
SCHEMBL2328642 0.79 MAPT (0.47) BRD4HDAC1HDAC2HDAC3POLB
SCHEMBL16892194 0.79 BRD4 (0.46) BRD4HDAC1HDAC2HDAC3P2RX7
SCHEMBL20600166 0.78 BRD4 (0.50) BRD4HDAC1HDAC2HDAC3P2RX7
SCHEMBL22235274 0.76 BRD4 (0.43) BRD4HDAC1HDAC2HDAC3POLB
SCHEMBL14636507 0.75 BRD4 (0.69) BRD4ALDH1A1POLBKDM4ESMN1; SMN2
SCHEMBL31391873 0.75 BRD4 (0.46) BRD4HDAC1HDAC2HDAC3P2RX7
SCHEMBL16886317 0.75 BRD4 (0.42) BRD4HDAC1HDAC2HDAC3ALDH1A1
SCHEMBL13714198 0.75 ALDH1A1 (0.39) ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. 2022-03-24 US disclosed
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. 2022-03-24 US disclosed
EP-3911652-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS Biogen MA Inc. (US) 2021-11-24 EP disclosed
WO-2020150626-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. (US) 2020-07-23 WO disclosed
WO-2020150626-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. (US) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS IRAK4, IRAK2, IRAK1 BRD4 116/4885HDAC1 720/4885HDAC2 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.